Literature DB >> 463663

Comparison of the ability of eosinophils and neutrophils, and of eosinophils from patients with S. mansoni infection and normal individuals, to mediate in vitro damage to schistosomula of S. mansoni.

M Vadas, J David, A Butterworth, V Houba, L David, N Pisani.   

Abstract

A reliable and reproducible method that produces separate fractions of pure eosinophils and neutrophils from normal peripheral blood was described. The interaction of eosinophils and neutrophils with antibody coated schistosomula was examined in vitro. Neutrophils were highly active in the 51Cr release assay and most formed rosettes with antibody coated red cells, but they adhered poorly to schistosomula and did not kill the organisms. Eosinophils, although they were less active in the 51Cr release assay than neutrophils and few formed rosettes, adhered strongly to schistosomula and, in the presence of antibody, were able to kill organisms. Organisms from patients with S. mansoni infection and eosinophilia were more effecient than eosinophils from normal individuals in their capacity to release 51Cr from labelled somula in the presence of antibody.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 463663     DOI: 10.1007/978-1-4615-9101-6_111

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel.

Authors:  Claus M Reimert; Colin M Fitzsimmons; Sarah Joseph; Joseph K Mwatha; Frances M Jones; Gachuhi Kimani; Karl F Hoffmann; Mark Booth; Narcis B Kabatereine; David W Dunne; Birgitte J Vennervald
Journal:  Clin Vaccine Immunol       Date:  2006-05

2.  Comparison of human eosinophils from normals and patients with eosinophilia.

Authors:  D A Bass; W H Grover; J C Lewis; P Szejda; L R DeChatelet; C E McCall
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.